Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Disc Medicine will present data across its entire portfolio at the ASH Annual Meeting in New Orleans, December 12-15, 2026, including three oral presentations. Orals feature RALLY-MF Phase 2 data for selcodebart (DISC-0974) in myelofibrosis anemia and RESTORE-PV Phase 2 data for DISC-3405 in polycythemia vera, plus initial Phase 1b DISC-3405 data in sickle cell disease in poster form. Bitopertin, the lead asset, gets a Phase 3 APOLLO baseline-characteristics poster and preclinical orals, following what management calls highly successful APOLLO topline results.
Key figures
- Drug Name
- bitopertin
- Phase Of Trial
- Phase 3
- Conference
- ASH Annual Meeting, December 12-15, 2026, New Orleans
- Oral presentations
- 3
- Programs presenting
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.